Olanzapine Pamoate is a small molecule drug with a maximum clinical trial phase of IV that was first approved in 2009 and is indicated in schizophrenia. This drug has a black box warning from the FDA. It is grouped under the following drug class(es): Mood stabilizers and Psychotropic agents. Its therapeutic use is listed as central nervous system (CNS) agents and mood stabilizers. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Zypadhera, olanzapine embonate and Olanzapinepamoatemonohydrate. Its PubChem CID is 135566032.
Olanzapine pamoate
| CAS No | 221373-18-8 |
|---|---|
| Molecular Formula | C40H38N4O7S |
| Molecular Weight | 718.8 g/mol |
| Synonyms | 4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid;2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine;hydrate |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Olanzapine Pamoate is a small molecule drug with a maximum clinical trial phase of IV that was first approved in 2009 and is indicated in schizophrenia. This drug has a black box warning from the FDA.
The listed CAS number is 221373-18-8.
The listed molecular formula is C40H38N4O7S.
The listed molecular weight is 718.8 g/mol.
4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid;2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine;hydrate.
The source lists Zypadhera, olanzapine embonate and Olanzapinepamoatemonohydrate.